Hyperlipidemia Clinical Trial
Official title:
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
The purpose of this study is to evaluate the effectiveness of a food-source nutrient containing bitter orange by comparing changes 45 blood chemistries and self-reported quality of life.
To evaluate the safety and efficacy of a food-source nutrient by comparing changes in total
cholesterol levels, 44 other blood chemistries, and self-reported quality of life as a
function of consuming two different functional-food supplements versus a placebo in a 60-day
study.
Upon completion of the pre-study screening, and after having received an explanation of the
requirements, risks and benefits, and completing the informed consent interview with the
research coordinator, subjects will execute a written informed consent. Subjects will be
randomly assigned to one of three study groups.
Relevant Background Information.
A factor leading to development of vascular disease, a leading cause of death in
industrialized nations, is elevated serum cholesterol. It is estimated that 19% of Americans
between the ages of 20 and 74 years of age have high serum cholesterol. However, in an
analysis of 10,000 test results in our database from subjects similar to those who are
likely to participate in this study, we found 37% of subjects had TC scores between 200 and
250 and 10.3% above 250.
The most prevalent form of vascular disease is arteriosclerosis, a condition associated with
the thickening and hardening of the arterial wall. The regulation of whole-body cholesterol
homeostasis involves the regulation of intestinal cholesterol absorption, cellular
cholesterol trafficking, a modulation of cholesterol biosynthesis, bile acid biosynthesis,
steroid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins.
Regulation of intestinal cholesterol absorption has proven to be an effective means by which
to regulate serum cholesterol levels.
Ad-Chol-Pre (ACP) is a functional food ingredient designed to inhibit cholesterol
absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1
(Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the
cholesterol-uptake inhibitor, Ezetimibe. In previous unpublished pilot studies examining the
safety and efficacy of ACP include:
- ACP was shown to produce a statistically inhibition of [3H]-Cholesterol absorption from
50 ug/ml (P<0.05) in NPC1L1 over-expressing HepG2 cell lines as compared to an
inhibition of 10ug/ml with Ezetimibe alone.
- I preliminary unpublished animal studies, ACP was shown to significantly inhibit
radiolabelled cholesterol. ACP was found to significantly lower total cholesterol (38%
~56%) and LDL cholesterol (46~57%) in bloods from animals fed who had been fed a high
fat diet for 6 weeks.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02927184 -
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT04640012 -
Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03213288 -
Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status
|
N/A | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02979704 -
A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia
|
Phase 2/Phase 3 | |
Completed |
NCT02569814 -
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
|
Phase 1 | |
Completed |
NCT02280590 -
Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia
|
Phase 4 | |
Completed |
NCT02428998 -
Safety for 24 Weeks Intake of Korean Red Ginseng in Adults
|
N/A | |
Completed |
NCT01678183 -
Financial Incentives for Medication Adherence
|
N/A | |
Completed |
NCT01426412 -
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
|
Phase 1 | |
Completed |
NCT01694446 -
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose
|
N/A | |
Completed |
NCT01131832 -
Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols
|
Phase 4 | |
Completed |
NCT00758303 -
A Study to Evaluate the Lipid Regulating Effects of TRIA-662
|
Phase 2/Phase 3 | |
Completed |
NCT00534105 -
Lipid Metabolism in Gestational Diabetes
|
N/A | |
Recruiting |
NCT00408824 -
Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)
|
N/A | |
Completed |
NCT00362206 -
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
|
Phase 3 | |
Terminated |
NCT00299169 -
Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes
|
Phase 4 | |
Completed |
NCT00381992 -
Risk Assessment of Long-Haul Truck Drivers
|
N/A | |
Completed |
NCT00701454 -
Survey of Thai-Muslim Health Status
|
N/A |